Winning
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
To be blunt, it's because you offered nothing new. Everything you mentioned was already well known and factored into the PPS. And as a result you came off like an amateur with an agenda. Especially with your screen name being what it is.
If somebody invested in this without knowing the very basic status of the company then they will be forever doomed in all of their trades. No amount of 'I just want to inform people' will help those people.
Everybody else, the majority, just viewed you for what you made yourself look like. An amateur with an agenda. Additionally, because 99% of the time, people that write on message boards that beg for others to listen, just want attention and really don't know squat about the company anyways. I look at you and say to myself, 'Even a broken clock is right twice a day.'
Change your screen name, offer people something new or rare. Dare I say, something introspective. Prove that you know something about the industry you're bashing and maybe you'll get a little respect. Until then, you'll just keep your status as an amateur basher. Same goes for pumpers.
Odds for an aftermarket 10K or other PR?
I give them until April 1st. By then the 10K for 2010 should be out. Obviously, the financials are going to be atrocious. That's obvious. That's expected and it's already factored into everything. The outlook is what's important. If they fail to show that they can turn crap into roses, they're doomed.
This will be the first reported financial by the new CEO. This is his time to make a splash. All new CEO's use a 10K or 10Q to introduce themselves to investors and outline their strategy for the company. Investor's 'Hope' is the only thing keeping this thing alive. By the decrease in volume over the last couple days, even that seems to be fading now. If Tilton remains silent and fails to show that he is interested in or able to increase shareholder confidence, bye, bye PPS. Hello St. George default. Helix will fall further into the depths of just being a shell with no viable future.
If green energy start-ups continue to lose people money due to corrupt and inept management, it'll never grow. For Helix, its time to sh&t or get off the pot.
At least I have my Alberta Bakken Oil play to fall back on.
CEO releases Letter to Shareholders
Dear Fellow Shareholders,
2010, while a very challenging year for NewCardio, was one of continued progress in developing and realizing the underlying value of our 3D cardiovascular diagnostic platform technology. NewCardio continued to build on our core science, technology and operations strength in 2010 to support the strategic development of our 3D platform technology. This commitment and focus by the entire NewCardio team was, and remains, on achieving, and exceeding the goals of our key initiatives, those being driving QTinno® commercialization and attracting strategic funding to advance the development of CardioBip™ and my3KG™.
We have proven the viability and robustness of the technology in the delivery of our initial product, QTinno, while remaining focused on the continued development of our novel 3D cardiovascular diagnostic platform technology. Simultaneously, we have continued to advance our second and third solutions, CardioBip, which captures and wirelessly transmits a full 12 lead ECG for the remote monitoring of chronic cardiovascular patients, and my3KG, which enables the more timely and accurate assessment of acute coronary syndrome in urgent care settings. Through our scientific and marketing efforts, we have established a high level of awareness of the value proposition in applying our advanced technology to the current issues in utilization of the electrocardiogram (ECG) as one of the primary diagnostic tools for cardiovascular disease. Management remains convinced of our ability to develop solutions that will advance the diagnostic value of the ECG, ultimately saving time, costs and lives.
In 2010, NewCardio transitioned from a development to a commercial stage company, achieving a number of key milestones, to include realizing our initial revenues for QTinno. This demonstrates the commercial opportunity for our initial solution and validates the regulatory and commercial viability of our underlying 3D platform technology. To ensure effective delivery of quality solutions in a timely and profitable manner, we have also transitioned the management from research and development to a commercially driven focus. We formalized our going-to-market priorities and implemented a more disciplined approach to our strategic and operational planning. We have built a scalable, regulatory-compliant infrastructure to effectively deliver our solutions in a cost effective manner. Management is focused on quality management, revenue generation and expense management, and believes this will maximize value creation for our shareholders, customers and employees and will make us a more attractive partner for our current and future investors and strategic partners.
The results of this continued progress and advancement will be the ongoing delivery of solutions that enhance the value of the ECG. These ongoing efforts, as mentioned earlier, are focused in two primary areas: 1) driving QTinno commercialization and, 2) attracting strategic funding to accelerate the development of CardioBip and my3KG.
During the year, our sales and marketing efforts for QTinno aggressively moved forward, involving educational and collaborative initiatives with all of the key industry constituents. We built upon the initial marketing successes and have realized the following successes:
* Signed an additional four Master Services Agreements (MSA) with clinical trial service providers who will use QTinno as their technology platform in delivering fully automated early Phase QT results to their drug sponsor customers. This provides NewCardio with a solid presence in Phase I units globally, ensuring that we will have a growing awareness of the QT study opportunities as this segment of the clinical drug development market strengthens in 2011.
* Realized initial revenues through a combination of ECG licensing fees as well as professional services fees in support of the implementation and validation of QTinno for customers. The ECG licensing fees represent the initial fully automated studies secured by customers, while the professional services fees enable us to accelerate the time to market for customers. At the end of 2010, all of our customers had fully integrated and validated QTinno into current clinical workflows and were proactively marketing their ability to deliver high quality cardiac safety analysis in a more timely and cost effective manner than the current methodologies allow.
* Collaborated with the Cardiac Safety Research Consortium (CSRC) in validating QTinno against their blinded “testing” dataset. The CSRC results showed that fully automated QTinno measurements were highly accurate and demonstrated significantly reduced measurement variability relative to the measurements submitted to the FDA by the pharmaceutical sponsor. These CSRC findings provide independent and authoritative validation of the QTinno value proposition that we believe will resonate deeply with potential QTinno customers. Results were presented jointly by CSRC and NewCardio scientists at the Annual CSRC meeting held at the FDA Headquarters in December of 2010. We know of no other automated cardiac safety solution provider that has accepted the CSRC validation challenge.
* Developed intelligent extraction algorithms, as part of the core QTinno solution, further enhancing QTinno’s ability to deliver higher-quality cardiac safety analysis in a much more timely and cost effective manner that the current ECG core labs. By automating and optimizing the ECG extraction process, we believe that drug sponsors will be able to conduct QT studies with significantly fewer study subjects without sacrificing study power. Continuous improvements such as this will ensure that NewCardio maintains its leadership position in delivering the most advanced cardiac safety solution in the industry.
Management expects market awareness and adoption to accelerate in 2011, and in the first three months we are already seeing a significant increase in the interest on behalf of the drug sponsors in better understanding how QTinno would be incorporated into their early Phase QT study programs. Recently QTinno was selected by one of the top five pharmaceutical companies for the cardiac safety analysis in two early phase studies. In an industry that is known for “me too”/“follow the leader” philosophies, we have positioned QTinno as the clear scientific and technology leader. Our close collaboration with the key industry leaders positions NewCardio well for capturing a growing market share as automation takes hold.
The team continues to work closely with strategic advisors to identify opportunities for securing strategic funding to advance the development of CardioBip and my3KG. We continue discussions to secure this funding and the strategic partnership/network that will leverage the actual funding. While these initiatives always take longer than anticipated, we remain hopeful that the exercise will result in a partnership that strengthens NewCardio in the long term and not just in its ability to deliver on the promise of CardioBip and my3KG. We expect to communicate the results of these efforts in the near future.
Finally, while focused on QTinno and strategic funding as “job1,” NewCardio remains more than a one-solution company. All of us at NewCardio joined the team not simply because of the promise of QTinno, but because of the unique and compelling 3D platform technology, which can support multiple products and solutions in advancing the diagnostic value of the ECG. We have recruited a world class scientific, technical, operational and managerial team to leverage this platform technology. This team truly believes in the potential to add value to each and every one of the 250 million plus ECGs performed annually in the developed world.
The entire NewCardio organization believes CardioBip will become a game changing solution in the evolving telemedicine and mobile health industry as it is the only remote monitoring tool which can effectively capture and transmit a full 12 lead ECG for analysis and review. We have extended our clinical study focused on the diagnosis of atrial fibrillation and continue to receive very encouraging and promising findings. Preliminary results show substantial promise for CardioBip to detect atrial fibrillation recurrence much earlier than standard follow-up.
The Company continues to experience an increase in the number of acceptances of scientific and medical submissions for presentation at leading trade shows. Most recently, we have been accepted to present the results of our latest clinical findings at the annual Heart Rhythm Society meeting (HRS) in May. These achievements are significant in increasing industry awareness of the potential of NewCardio’s science and technology and in CardioBip’s ability to become the emerging leader in the growing wireless remote monitoring market.
my3KG has experienced break through findings as the team continues to develop the underlying algorithms and tests them internally against databases acquired from our research partners. Dr. Ihor Gussak, our Chief Medical Officer, presented the results of NewCardio’s recently completed clinical study showing that this solution had substantially greater accuracy than the standard 12 lead ECG in diagnosing Acute Myocardial Infarction, or AMI, in diabetic patients. With current technology, accurate diagnosis of AMI is notoriously difficult in diabetics, largely because the standard 12 lead ECG is particularly inaccurate in this patient group. This is an important result because diabetes currently affects over 10% of adults in the US, and the incidence of AMI is two to four times greater in diabetics than in the general population, according to the American Diabetes Association and the American Heart Association. More accurate and timely diagnosis facilitated by the my3KG may lead to improved clinical outcomes in diabetics with heart conditions. We believe that these findings represent the tip of the iceberg on the potential of my3KG and more importantly our 3-D software platform technology.
What attracted the team to NewCardio – the potential of the 3D software platform technology – is starting to be realized. The commercialization of QTinno validates the platform and continues with our other solutions. For 2011, our strategic and tactical goals and objectives remain focused and consistent:
* Grow market awareness and adoption of QTinno to achieve steady revenue growth
* Secure strategic funding to accelerate the development, validation and commercial delivery of CardioBip and my3KG.
As funding is achieved and QTinno commercialization expands, we expect to deliver on the potential and translate it into the creation of value for our customers, shareholders and employees, and probably, most importantly, to those people whose lives will be enhanced by our solutions. I would like to thank you for your continued support of our efforts.
Sincerely,
Vincent W. Renz, Jr.
President and CEO
Debt restructuring agreement. By looking at past agreements, perhaps we can speculate on what a new one would like. This is an agreement with NIR I found from 2008.
In the first quarter of 2008, the Company entered into discussions with the NIR Group, LLC with the intent of restructuring all of the Company's outstanding debt obligations to AJW Capital Partners, LLC, AJW Offshore, Ltd., AJW Qualified Partners, LLC and New Millenium Capital Partners II, LLC. In September 2008, a payment of approximately $1.3 million was due and payable. The Company did not make the required payment nor did the debt holder issue a default notice, due to the ongoing negotiations. The Company has reached an agreement in principle, subject to the execution of definitive documents, in which the NIR Group, LLC has agreed to consolidate and extend the maturity date on all notes for three years to October 2011. The terms and conditions of this restructuring will be part of the definitive agreement, which the Company expects to execute by the end of November 2008.
Accumulation levels are back up to where they were last April-May. (1 year chart) Hovering around 40 million. Say whatever you like, but it shows more investors are buying and holding. The last week has brought on some volatility as some investors are running around like chickens with their heads cut off, unsure what to do. I expect accumulation levels will rise to new highs, sooner rather than later.
NWCI Recently above it's 200 Day MMA. Sitting at .85, .95 is the ask. Only one MM sitting on it. Extremely thin! Also, moments ago, in the conference call today it was announced that Merck has selected NWCI as its automated cardiac safety solution, for two Phase I drug safety studies.
Add to that a very low float, and heavy accumulation, this will shoot up high with any volume.
Merck has been identified in the conference call as the top Pharma that ordered the 2, Phase 1 drug safety studies as stated in the March 17th PR:
SANTA CLARA, Calif., March 17, 2011 /PRNewswire/ -- NewCardio, Inc., (OTC Bulletin Board:NWCI.ob - News) a cardiovascular diagnostic solutions developer, announced today that a top 5 global pharmaceutical company has selected QTinno®, their automated cardiac safety solution, for two Phase I drug safety studies. Fully automated ECG analysis, empowered by QTinno, will be delivered by the ECG core lab of a top 3 Clinical Research Organization (CRO) under the terms of an existing Master Services Agreement with NewCardio.
The studies start in March and are expected to be complete by June of 2011. QTinno was selected based on its proven ability to enable the CRO to deliver high-quality results in a much more timely and cost effective manner than the current core ECG lab methodologies. Turnaround time was a critical factor in choosing QTinno in these studies, as the sponsor needs to present the results to the FDA for review after Part 1 of the initial study in order to develop the requirements for Part 2 of the study, to be started shortly after the completion of Part 1. NewCardio expects to recognize revenue from the studies in the first half of 2011.
Vincent Renz, NewCardio President and Chief Executive Officer, commented, "We are excited to participate in these important studies, and gratified that a major global pharmaceutical company specifically identified QTinno for automated analysis of all the ECGs from the studies. QTinno's selection for these studies provides clear evidence of the pharmaceutical company's confidence, not only in the accuracy and precision of QTinno's fully automated ECG analysis, but also in the FDA's willingness to accept drug safety data from properly validated technology such as QTinno. We expect that QTinno will play an increasingly important role as the drug development industry accelerates their adoption of the higher quality, cost effective cardiac safety analysis."
"This selection represents further evidence of the increasing market adoption of QTinno, not only as a validated methodology, but also as a clear leader in delivering advanced technology solutions for the drug development industry," Mr. Renz continued. "Our business model as a technology developer, not an ECG core lab, enables us to work effectively with all of our customers and partners as we are not competing with them but rather equipping them with solutions and enabling them to deliver enhanced clinical trial products and services. We are pleased that industry leaders are embracing QTinno, and we look forward to an accelerating adoption cycle with increasing market penetration."
About QTinno Technology
NewCardio's patented QTinno 3-D ECG software technology is a novel, fully automated program for evaluating QT and other timing intervals relevant for assessing drug cardiac toxicity in drug development. It provides fast, accurate and precise QT data from a broad range of challenging ECGs and enables reliable, automated identification of key cardiac events. Pharmaceutical sponsors and clinical research organizations, which are mandated by the FDA to test new drugs for potential cardiac toxicity, are expected to benefit from QTinno's faster, more accurate and less expensive assessment of cardiac status.
Merck selected Newcardio inc, NWCI, for it's QTinno® product, for use for their automated cardiac safety solution, for two Phase I drug safety studies.
Fully automated ECG analysis, empowered by QTinno, will be delivered by the ECG core lab of a top 3 Clinical Research Organization (CRO) under the terms of an existing Master Services Agreement with NewCardio.
The studies start in March and are expected to be complete by June of 2011.
a) Authorized
Unlimited number of common shares.
b) Issued and outstanding
# of shares: September 30th, 2010: 186,283,373
$ amount: $42,440,981
Bowood Announces Spud of Alberta Bakken Well at 15-25-3-23 W4
FOR IMMEDIATE RELEASE TSX VENTURE EXCHANGE: BWD
March 24, 2011 – Calgary, Alberta – Bowood Energy Inc. (“Bowood” or the “Company”) is pleased to announce that its first joint well operated by Legacy Oil + Gas, in the southern Alberta Bakken fairway spudded on March 22nd, 2011 and is currently drilling ahead. The proposed Spring Coulee 15-25 horizontal well is being drilled from a surface location in 3-1-4-23 W4 with the horizontal portion of the well expected to terminate in 15-25-3-23 W4. The well‘s primary targets are the Big Valley, Exshaw and Banff Formations, which collectively form the Bakken petroleum system in the southern Alberta Basin.
The 15-25-3-23 W4 well targets an area where there is not only potential in the Bakken Petroleum system but also in a number of other zones prospective for oil.
The Spring Coulee 15-25 well is the 28th well licensed by industry in the fairway on the Canadian side of the border since the play emerged in 2010.
With operations based in Calgary, Alberta, Bowood Energy Inc. is a TSX-V listed company engaged in the acquisition, exploration, development, and production of oil and gas resources in Alberta. Bowood is recognized as a TSX Venture 50® company in 2011. TSX Venture 50 is a trade-mark of TSX Inc. and is used under license.
For
NWCI continues it's uptrend after breaking the 200 day MMA
http://investorshub.advfn.com/boards/board.aspx?board_id=13573
That the best you got? Lol.
That would be amazing! The only reason people are selling is to move their money into something else. Hopefully, more people will do so. Would love to get some .0001's!
Hell, the new CEO is heavily involved in 2 other companies that could use Helix. Anything can happen with Tilton now.
Thanks! Another major play is ROAOF, Bowood Energy, a small company that will be most likely bought out by big oil in the Alberta Bakken.
Coming off consolidation. Canadian ticker is BWD. Trades on two tickers.
http://stockcharts.com/h-sc/ui?s=ROAOF&p=D&b=5&g=0&id=p25141740733
http://investorshub.advfn.com/boards/board.aspx?board_id=20576
ROAOF Bowood Energy. Huge Oil play in the Alberta Bakken.
Drilling starts before April. Rebounding off of it's recent consolidation.
http://stockcharts.com/h-sc/ui?s=ROAOF&p=D&b=5&g=0&id=p25141740733
ROAOF Bowood Energy. Huge Oil play in the Alberta Bakken.
Drilling starts before April. Rebounding off of it's recent consolidation.
http://stockcharts.com/h-sc/ui?s=ROAOF&p=D&b=5&g=0&id=p25141740733
NWCI 200 Day Moving Average surpassed. Uptrend confirmed!
http://stockcharts.com/h-sc/ui?s=NWCI&p=D&b=5&g=0&id=p55011721999
NWCI 200 Day MA broken. Uptrend confirmed!
http://stockcharts.com/h-sc/ui?s=NWCI&p=D&b=5&g=0&id=p55011721999
All that happened today was just traders moving money around. No reason to sell other then to move into something that is moving right now. Happens every time there is a large uptick in the general markets. All those sellers will be back.
IMPORTANT: 2 TICKER SYMBOLS FOR BOWOOD ENERGY.
Bowood is a Canadian Company, that thru an American acquisition, the company kept it's American ticker as well. For those in the US, the company trades under ROAOF. For those in Canada, its BWD.
A further description is layed out in the company information above.
Again,
ROAOF is the American Ticker
BWD is the Canadian Ticker.
Welcome to Bowood Energy's iHub board.
This is a new board as of March 21st, 2011
Come one, come all.
ROAOF: BOWOOD ENERGY.
Monster oil & gas play in the Alberta Bakken play.
Coming off of consolidatiion. Huge acquisition possibilities.
http://investorshub.advfn.com/boards/board.aspx?board_id=20576
That info is available in the last 10K. For more updated info, you'll have to wait until the 10Q comes out march 31st. That will be for 2010 4thQ. For more current, you'll have to wait for the 1st Q 10K which won't be out until april-may.
Top 5 Global Pharmaceutical Company Selects NewCardio's QTinno for 2 Upcoming Phase I Drug Safety Trials
Fully Automated ECG Analysis, Empowered by QTinno, to be Delivered Through Integrated Clinical Trial Services Provided by Top 3 CRO
SANTA CLARA, Calif., March 17, 2011 /PRNewswire/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiovascular diagnostic solutions developer, announced today that a top 5 global pharmaceutical company has selected QTinno®, their automated cardiac safety solution, for two Phase I drug safety studies. Fully automated ECG analysis, empowered by QTinno, will be delivered by the ECG core lab of a top 3 Clinical Research Organization (CRO) under the terms of an existing Master Services Agreement with NewCardio.
The studies start in March and are expected to be complete by June of 2011. QTinno was selected based on its proven ability to enable the CRO to deliver high-quality results in a much more timely and cost effective manner than the current core ECG lab methodologies. Turnaround time was a critical factor in choosing QTinno in these studies, as the sponsor needs to present the results to the FDA for review after Part 1 of the initial study in order to develop the requirements for Part 2 of the study, to be started shortly after the completion of Part 1. NewCardio expects to recognize revenue from the studies in the first half of 2011.
Vincent Renz, NewCardio President and Chief Executive Officer, commented, "We are excited to participate in these important studies, and gratified that a major global pharmaceutical company specifically identified QTinno for automated analysis of all the ECGs from the studies. QTinno's selection for these studies provides clear evidence of the pharmaceutical company's confidence, not only in the accuracy and precision of QTinno's fully automated ECG analysis, but also in the FDA's willingness to accept drug safety data from properly validated technology such as QTinno. We expect that QTinno will play an increasingly important role as the drug development industry accelerates their adoption of the higher quality, cost effective cardiac safety analysis."
"This selection represents further evidence of the increasing market adoption of QTinno, not only as a validated methodology, but also as a clear leader in delivering advanced technology solutions for the drug development industry," Mr. Renz continued. "Our business model as a technology developer, not an ECG core lab, enables us to work effectively with all of our customers and partners as we are not competing with them but rather equipping them with solutions and enabling them to deliver enhanced clinical trial products and services. We are pleased that industry leaders are embracing QTinno, and we look forward to an accelerating adoption cycle with increasing market penetration."
About QTinno Technology
NewCardio's patented QTinno 3-D ECG software technology is a novel, fully automated program for evaluating QT and other timing intervals relevant for assessing drug cardiac toxicity in drug development. It provides fast, accurate and precise QT data from a broad range of challenging ECGs and enables reliable, automated identification of key cardiac events. Pharmaceutical sponsors and clinical research organizations, which are mandated by the FDA to test new drugs for potential cardiac toxicity, are expected to benefit from QTinno's faster, more accurate and less expensive assessment of cardiac status.
The new CEO needs to make a statement on where he's going to try and take the company. His current affiliations show some promise.
Its usually a common practice for a new CEO, especially one that comes from outside of the company, unlike Scott Weinbrandt, & Kevin Caludio whom were promoted from within, by default, to make a statement of "Hey here I am, this is who I am, and this is what I plan to do". Perhaps we'll just have to wait until the 10Q, March 31st to hear anything. In the words of Ricardo, "Luuuucy, you got a lot of explaaaaaaining to do."
Joe already gave me an update on the contracts. When he is legally able to give out more info he will. He's not going to give out insider info. When the company can afford to become fully reporting they will. The debt restructuring has a wrench put into the gears. That is Joes's fault for dealing with the devil (NIR) in the first place. Everything rides on the debt restructuring. With that in place, they'll get some working capital, which will enable them to move forward with their other projects, which will result in increased shareholder value. Before that happens, the FBI probe on Corey Ribotsky has to end. Guilty or not guilty, nothing moves seriously forward until that is ordeal is completed.
Like I've said before, many times, JOE DOES NOT CARE ABOUT DAY-TRADERS OR FLIPPERS! WE ARE NOT INVESTORS! And we don't care about him or his company in return! Who here is going to hold this for 20 years!? Who is a real investor in this stock? Who is going to remain long in this for 5 years? 2 years? Anybody? Buehller? The ones that are in this for the long haul, aren't on this board or any other. They aren't the 'Common share holders'. Joe works for those people. He will do things accordingly and in his own time, regardless of how long it takes. For us, 6 months is a lifetime! To him and real investors, it's a blip. "Darn you Joe! I tried to buy your stock and get rich by dumping it on a couple ticks up! Why don't you care about me!" That's what you sound like.
If you did your research, you would see that the stock traded in this range for much longer, last year. Until the NIR probe is finished, nothing big will happen. It will continue with its magazine. The company has a product. The stock will not get revoked. When stuff does start happening, they will try to effect a reverse split. I will be out before then. Additionally, the SEC doesn't waste it's time on penny stocks. There are far worse companies guilty of far worse offensives. That's why the SEC warns traders about pennys. Because they are UNREGULATED!
As far as Joe's word goes, I take everything for what its worth at the given time. I never believe everything. Not from anybody! I'll take what he tells me and DD it.
As for knowing how to play penny stocks, I am not perfect. Nobody is. In a world where 2+2 can = 9, how can anybody be? But I win more then I lose. And my percentage gets better at it with each trade. I've learned, with great difficulty, not to trade on emotion. I suggest others do the same. Technically, I haven't lost here yet, as I still hold all my shares. I'm just down. But not for long. :)
Good luck to you and everyone else here.
LOL, I'm not here to fix pennystock land. I know what it is. I accept what it is. I win and I lose. You seem to want the shark to act like a dolphin. It isn't going to happen. Yes, pennystock land is corrupt. Yes, many of the CEOs suck! Yes, many people get scammed. But that's the nature of the beast. That's what it is! That's the name of the game! When you win, I'm sure your all about it. Its only when you lose that you start bitching. Your type is pathetic. When things don't go your way, you take your ball home. Am I right?
You refuse to accept the reality of the situation! You seem to think that Penny stocks should be all rosy and glamorous. Go take a trip down the rabbit hole and maybe you'll find that world. You obviously don't have the skin for this type of trading, so go play the safer ones. Don't swim with the sharks if you don't want to get bit. Go swim with the Koi.
The SEC has given out many warnings about Pennyland. Every investor knows the risks going into any company in this arena. We all know 2 + 2 doesn't always equal 4! Yet we gamble anyways! Because its fun and you can make a lot of money. If you can't afford to lose your money, you shouldn't be playing. If you bet your house, you shouldn't be playing. If you believe everything you read from a company in this arena, you shouldn't be playing. Take responsibility for your ignorance. I do for mine.
You act like you just found out about the risks after you bought. If you bought without doing your DD, take responsibility for that. It appears you have no idea how to trade these things. As for "letting people walk all over me", that's just moronic. Its like playing 21 in vegas. If the dealer beats me, I lose. What do you do, scream at him for beating you and say your just sticking up for yourself for losing? Investing in a very problematic company and then yelling at it for it's problems is illogical. Grow up or continue to eat your meals at the kiddie table.
If Joe gos on vacation with my money, good for him. I'll be going on one with his soon enough. I have a great mutual understanding with Joe. I can ask him anything. If I make you sick, go get a shot and leave.
That would be a dream come true! Would love to add more at that level. But it won't happen. As all the Lemmings head towards the cliffs to make their jump, this is holding it's own. Lot of blue-light specials elsewhere though! I absolutely love irrational sell-offs like these.
Its been a while since I have been back here looking at ZVTK. At .0011, it's back on my radar. From what I have read, they haven't started the advertising campaign yet for the Gung H20. It will begin during the summer, I guess.
"Our sales strategy calls for a national
marketing campaign going full throttle during the summer months when water issues are
expected to be daily national news.” said Rob Babkie, CEO of Zevotek
I see they will depend on the Ionic Bulb to get them thru until then. So far they only have $7884 in sales for the current fiscal year that started in July. They'll need 10 times that much this quarter.
It is tempting to buy back in and try and make back what I previously lost. This will be on my daily watchlist.
Duh, of course it stinks. Its a .0001 priced company. What did you expect??? Microsoft? You sound like your shocked that this happened. If you're going to pet the snake, don't get mad or bitter if you get bit. I'm down a sizable chunk myself. It sucks. But it is what it is. If you are really invested and taking a hit, that sucks to.
Frankly, when it comes to a penny stock, I don't think non-invested parties are going to post negative stuff, time and time again, unless they want it to go down for entry or to cover.
And for those that are invested in it and loosing, constantly berating the company does your position no good, letting your emotions control your trading. Calm frigging down already.
It accomplishes nothing.
If I was Joe and some daytrader flipper, who cares nothing for my company, who is just playing it for a quick gain, as we all are, calls me up to complain, I'd tell them to jump in a creek. I have had multiple back and forths with Joe and he has been pleasant with me each and every time. From the tone of your posts, I doubt you came off as being professional.
Not one investor here is using this company, to retire on or hold for the next 20-30 years. We all played it for a quick play. We are all holding bags now because we played it wrong. If Joe made money off of us, good for him. He played it smarter. We'll get him next time. And that will be sooner rather than later.
Supposed to, yeah, but they didn't. Lesson number one. To a CEO, don't issue stuff saying when you expect something to happen because timelines are never accurate for a penny company. Lesson #1 for an investor. If you believe a "we expect this at this time"
statement from a penny CEO, you will lose nearly every time.
In correspondence to me, from early last February, Joe stated ".....a delay in getting started on two of our military contracts has made cash flow a bit troubling. But that part should be addressed shortly as one of the three contracts we do have were released to us last week and we ought to be getting started on the others later this month or in March."
Take it for what it's worth. I dunno what your general stance is on the company. You appear to dislike it. I assume that you just want to get it to no-bid. I would loooooove the ask to go to .0001 so I could buy the hell out of it. So, good luck with that.
In all sense of things, EPGL is doing exactly what a company, with the problems they have, does. For anyone to be angry with Joe is a complete waste of thought and emotion.
From Joe's correspondence, it would appear that there is a possibility that stuff will start happening soon. If it doesn't, then it doesn't. Nothing really concrete can be done anyways until they get their debt restructured or eliminated. Being that Corey Robotsky has the reputation of being Satan, I don't think a restructuring deal involving them will come without some sort of price. Hopefully, he'll end up in jail soon and NIR will be broken up. Hopefully, the debt will be bought by somebody less scrupulously evil, enabling a deal to be made that's best for everybody.
All and all, regardless of mine or anybody else's feelings towards Joe or the company, it is what it is. Right now, this is flipping stock. It will be flipped at every tick up or down. Until they start reporting and get things squared away, they will remain on the bench in the big game. But they won't be kicked off the team. Thoughts of them being revoked is amateur. An R/S is more likely, but that won't occur until the company is off of the bench and running. And by then 90% of everybody here, including myself, will be gone anyways, having sold at .0004-.0005. So I could careless about that.
There are far worse companies out there to be stuck in.
NewCardio to Conduct Corporate Update Conference Call on March 29, 2011 Conference Call to Follow Release of Fourth Quarter 2010 Financial Results at 4:30 p.m. ET
SANTA CLARA, Calif., March 15, 2011 /PRNewswire via COMTEX/ -- NewCardio, Inc.
(OTC Bulletin Board: NWCI), a cardiovascular diagnostic solutions developer,
announced today that the Company expects to file its Form 10-K for the year
ended December 31, 2010 on March 29, 2011 and management will conduct a
conference call to provide a corporate update and discuss progress as follows:
What: NewCardio Corporate Update Conference Call
When: 1:30 p.m. PT/ 4:30 p.m. ET, Tuesday, March 29, 2011
Where: Please dial 1-888-846-5003 (domestic) or 1-480-629-9856 (International)
five to 10 minutes before the call. Investors will also have the opportunity to
listen to the conference call and the replay on the News and Events section of
the NewCardio website at: http://www.newcardio.com.
Questions: Select questions for the conference call will also be taken via email
at nwci@haydenir.com and can be sent any time prior to the conference call's
starting time.
Replay: A replay of the call will be available by dialing 1-877-870-5176
(domestic) or 1-858-384-5517 (international) and referencing passcode 4425345.
NewCardio to Present Study of my3KG Performance at the Society for Academic Emergency Medicine Annual Meeting.
Mar 15, 2011 (Close-Up Media via COMTEX) -- NewCardio, Inc., a cardiovascular
diagnostic solutions developer, announced that the results of a my3KG
performance study will be made at the Society for Academic Emergency Medicine
(SAEM) Annual Meeting, to be held in Boston, June 1-5.
According to a release, the study, entitled "A New Computer Algorithm Performs
Better than Cardiologists in the Diagnosis of Acute Myocardial Infarction," will
be presented at the SAEM meeting by Dr. Stephen W. Smith, Associate Professor of
Emergency Medicine, University of Minnesota and Hennepin County Medical Center
(HCMC), Minneapolis MN. Co-investigators in this study included Drs. Victor Romo
and James Miner, Emergency Medicine, HCMC; and Drs. Dajuanna Lakireddy, Subba
Vanga, and Sudha Bommana, Kansas University Cardiovascular Research Institute,
Kansas City, KS.
The SAEM presentation will address a key diagnostic problem in Emergency
Department (ED) patients the low diagnostic sensitivity of the standard 12-lead
ECG in early diagnosis of acute myocardial infarction (MI).
Dr. Smith commented, "The standard 12-lead ECG plays a critical role in MI
diagnosis, but its low sensitivity even with expert physician interpretation -
leads to diagnostic delays and errors. To the extent that my3KG can improve
diagnostic sensitivity for acute MI, it is an important result that may lead to
faster and more accurate MI diagnosis in the ED."
Dr. Ihor Gussak, NewCardio's Chief Medical Officer, commented, "We were
delighted that Dr. Smith collaborated with us in this study. He is an
internationally known and well-respected emergency medicine specialist with
particular expertise in clinical electrocardiology and diagnosis of acute
coronary syndromes. He is highly influential among ED physicians, who represent
a key potential constituency for my3KG. We look forward to the SAEM
presentation, and to completing additional studies with Dr. Smith and his
colleagues, as we further develop my3KG."
NewCardio noted that its 3-D ECG platform technology improves the accuracy and
significantly increases the diagnostic value of the standard 12L ECG. NewCardio
is developing the my3KG solution for urgent diagnosis of serious cardiac
conditions, including AMI. In clinical studies to date, the my3KG has shown
substantially improved diagnostic accuracy relative to the standard 12L ECG,
particularly in the most diagnostically challenging patients (such as those with
diabetes and electrical conduction abnormalities). Accordingly, the Company
believes that its my3KG solution will substantially improve diagnostic timing
and accuracy in life-threatening cardiac conditions, and will thereby improve
clinical outcomes for a broad range of cardiac patients. The Company plans to
file a 510(k) application in late 2011 or early 2012 for FDA approval to market
my3KG in the U.S.
The SAEM is dedicated to the improvement of care of the acutely ill and injured
patient by improving research and education. To achieve this mission, SAEM
influences health policy through forums, publications, inter-organizational
collaboration, policy development, and consultation services for physicians,
teachers, researchers, and students.
I would say that you put yourself into the position of a bagholder.
If you try and pet the snake, don't get mad at it for biting you.
The rest of this post is long as I can only post one per day, but i feel I have stuff to say. Some of it rambling, but some of it important to. :)
Definitely sucks, as I bought my first bag at .16 a year ago. I bought for a quick flip that never happened. I remember it well. There was nooooo way it could collapse anymore at the time. Ahhh, the age old saying. But, I did very little DD and suffered the consequences. Everything that plagues HLXW is available to the public. Yet next to nobody knows it. With all my averaging down, I was able to cut my losses in half with the latest pump. I will continue doing so until I have all my money back and can give HLXW the finger.
In this latest case, anytime a penny goes up on no news, odds are it's a pump. Regarding the OMRF article by ecofriends.com, a cheerleader of Helix, well, that should of been warning number 1. Anybody that bought without getting confirmation that they indeed got the contract back, well, you're looking at the results. If people never knew they lost the contract to begin with, before buying, well, good luck to you in this realm of trading. You're gonna need all you can get. People on this board tried to explain that, but we're labeled as bashers and I was even told I had "stinky breath". Granted, there were posters bashing for the sake of bashing. I got put on probation for responding to one. Lol. Every board has got them.
The best way to play this, now, for me, in order to finish my goal of getting all my money back, is to continue to see if there is more info that Helix is sitting on before releasing. Ie, the patent and the Bluewater verdict. I was hoping to make a killing on the patent info. But, I was unaware of all the bad news they planned to release just prior to it, killing any possible run it could of had. Again, all that bad news was available to the public beforehand. I just didn't look hard enough. Perhaps, that strategy by Claudio is finished, being that Tilton is now at the controls.
I still would love to see if anybody affiliated with Bluewater, St. George, IAB Island Ventures, or even Helix, were involved in this latest pump. Especially those that may have shorted it. I implore everybody to write to IR asking Tilton to look into the Myron Guslak deal. For those that don't know, Guslak sits in jail for stock fraud. He was also the managing director of Bluewater and the guy who was scamming Marcus Segal's other companies. For those that don't know, Marcus Segal ran the shell companies Helix merged with. For those that don't know, Helix inherited those deals Segal made with Guslak. For those that don't know, Segal took his money and ran after the Helix merger. For those that don't know, all the founders of Helix are now gone. And yes, they left with their pockets filled. I would like to know what Kevin Claudio is leaving with.
I'd like to see the board go into discussions about Tilton. Possibilities of another merger? With Girasolar, Inc.? Tiltons other green energy company where he is a member of the BOD
http://www.girasolar.nl/
http://investorshub.advfn.com/boards/board.aspx?board_id=5546
Imagine that for a second. Most successful wind companies have solar as well. Except Helix. Makes sense. However, Girosolar (GRSR) isn't the best company either. In fact it may be worse then Helix. Would kinda be like piss merging with crap. They're a grey market pinky that haven't reported since 2008. I'll start some DD on them tonight.
What's his history with SEA Tiger, Inc. Why did he leave once and come back?
World Series of Golf??? Well, I hope he spends more time in the office then on the golf course in San Diego. Perhaps he has some connections to some golf courses that can use wind power. Wind powered ball washers perhaps? That's something I'd be interested in.
Lastly, Savanna East Africa, Inc.
http://www.savannaea.com/
Tilton is their new CEO as well. As of a month ago. WTF.
Becomes a CEO of two companies in a month. Hmmmmm.
There is webcast about him on their site. It would be wise to register and watch!!! Link below!
http://www.savannaea.com/webcasts/wb_020311.html
Looks like the company has their hands in a lot of stuff. Basically deals with infrastructure development in East Africa, mainly Kenya. Imagine the possibilities with Helix there. I will start DD on that aspect tonight as well. Off the bat, it seems that Tilton is on the BOD of two green energy companies and is part of a giant company that deals with building infrastructure. Lets start connecting the dots. Could bode very well for these two struggling Green energy companies. HLXW and GRSR.
Now, its more important than ever to do DD. With Tilton the game is changing. The future may start to outweigh the past.
Inadequate DD is worse then no DD. Do it right! If we all do it and share, we all become smarter. With knowledge comes wealth.
As for my one allowable post per day, due to probation, that's it. See yall tomorrow.
Good luck.
One thing to keep in mind is that Bluewater Partners is potentially a very, very shady company. I would imagine that Bluewater will let this sit for a while and not put too much pressure on them to pay. The only reason, possibly, that Bluewater took them to court to begin with, was because they knew Helix couldn't fight it. The last thing they want is Helix's and Bluewater's history tossed around in a court of law. The Bluewater guy, Myron Guslak, who orchestrated the deal that Helix inherited, when they merged with Clearview Acquisitions currently sits in jail for stock fraud.
http://www.caymannewsservice.com/business/2010/11/18/cayman-mansion-owner-gets-six-years-jail-time
The deal with Clearview.
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=6310546
Guslak made a habit out of scamming Marcus Segal's other companies as well. Stargold Mines and Star Energy. BTW, Marcus Segal owned Black Sea Oil & Gas which changed its name to Clearview Acquisitions. Which then merged with Helix. They merged with Helix just weeks after Clearview initiated a 1-1000 R/S. Segal and his crew then resigned, took their cash and split. Fast forward one year later, the entire roof instantly collapses in on Helix.
As for the new CEO, Tilton, I feel, is the best guy for the job right now. I want a guy that can fully understand the numbers, crunch the numbers, and increase shareholder value. Odds are, this ship has been too badly damaged to sail again. But, regardless, it still has a sail and the ship is still floating. A patent makes for a pretty good patch kit. But there a lot of holes that need fixing. I will be trying diligently to get Tilton to look into the Guslak deal. Just as I have done with Claudio. As CFO since the beginning, Claudio had to of known about Guslak's dealings.
I give a Helix a 30% chance of surviving on its own. A 70% chance of being bought out. The product is still a great product. The recent article regarding the Navy is a great update.
The only reason it is down is because of potentially corrupt and unethical lenders, ie, Bluewater and St. George, where Myron Guslak and John Fife have both been convicted of stock manipulation/fraud.
Fife got off with fines and probation while Guslak sits in prison. Meanwhile, Helix has paid over 1.6 million to Fife in penalties and only god knows how much Guslak made since 2006 when his deals first started. But, perhaps, it all comes down to, and perhaps mainly, to the colossal blundering of Ian Gardner and Scott Weinbrandt as CEO and President. Bad business deals on their part such as the failure of the Abundant Renewable Energy, LLC, and the Renewable Energy Engineering, LLC, asset purchase, cost Helix over a million dollars. More importantly, it also resulted in their failure to raise 5 million bucks which essentially stopped all progress on international sales, cell phone towers, oil well pumping, etc, etc, and forced them into the toxic deal with St. George to stay alive. Couple that with Bluewater's deal....Ouch. The patent is their life support right now. It gives the company value. A heartbeat.
Now, consider manipulation by Helix. Their new MO seems to be announcing bad news with good news. They got their patent allowance on 18th of January. Learned they would get it in an interview with the USPTO on the 14th. But waited to announce it until after they announced the bad news. On the 26th. Same with the latest 8K. Those default judgments were granted the same day they were applied for. January 20th is when the courts granted the default to Bluewater. Helix says they received notice on March 2nd. 41 days after the judgment. Helix is supposed to have the option of appealing the decision 30 days after judgment. So, it is most likely, they were notified immediately after the verdict. Not 41 days afterwards!! Plus, it cost next to nothing to appeal. Granted, they would still not fight it, but it would grant them time. And they release it right after a blatant pump!!!?? My ass! Helix waited to announce it until they had good news to report in order to offset it. So basically, it appears that the patent news and the St George financing deal was meant to offset the loss of the OMRF deal, the loss of their manufacturer and the request for defaults by Bluewater, etc. The news of a new CEO was meant to offset the news of the default judgments. BTW, For what its worth, the Bluewater judgment is for $652,456.42. Not $647K. Just 5K more, but still. So, with all that in mind, I expect we'll continue to get the good with the bad. Perhaps its a good thing. Controls volatility.
Regarding the latest pump and dump....Ask yourself. Now that you know Bluewater knew of this judgment since Jan 20. Knowing that they have a history of corruption doesn't it make sense that they would short the living daylights out of this company during the latest pump and dump? I have no proof they shorted or that Helix shorted or that St George shorted or they had their friends short. Although, I do know that where's there's smoke there's usually fire. We are swimming with sharks. Expect to bit every now and then.
As for the PPS, remember, everything we know about the company is already factored into the price. People seem to forget that. Its at these levels for a reason. If it wasn't for the patent, this would be sub .0005's. The patent alone is keeping this above. As for monday, we'll see how the announced judgements and new CEO factors in. Which will outweigh the other?
This is my one allowable post per day for Helix, as deemed possible by the brains of iHub.
As for my position, I held 1,628,000 shares at an averaged down price of .0028ish. I sold 1,500,000 during the latest pump at .0014. I have 128,000 remaining. I plan to re-buy if it falls further. If not, I'll just hold what i got. Do your DD! Follow the money!
8k filed.
Hello Mr. Tilton. Welcome to the mess.
Good bye Mr. Claudio.
The funny thing about this is that all the default judgements occurred on January 20th. They only waited until now to disclose it...after the pump.
Effective as of March 11, 2011, the Board of Directors of Helix Wind, Corp. (the “Company”) appointed James Tilton to the Board of Directors to fill one of the vacancies existing on the Board of Directors, and appointed Mr. Tilton as the Company’s Chief Operating Officer. James Tilton, 50, served as the President, Treasurer, Secretary and director of SEA Tiger, Inc., an information technology company, from its inception in January 1999 until his resignation in 2005. Mr. Tilton was reappointed to these positions in 2009. Mr. Tilton has also served as Chief Executive Officer, President, Secretary, Treasurer and sole director of NuMobile, Inc., a mobile computing technology company, since its formation in November 1999. From 1995 to 1996, Mr. Tilton was a stockbroker at Morgan Keegan. From 1997 to 1999, Mr. Tilton worked independently in the securities industry, specializing in corporate finance and investment banking. Mr. Tilton also serves as a director of Girasolar, Inc. and World Series of Golf, Inc. Since February 2010 Mr. Tilton has also served as chief operating officer of Savanna East Africa, Inc. Mr. Tilton has a B.A. in Political Science with an emphasis in Accounting/Business from the University of Louisville. The Company believes Mr. Tilton's experience as founder of SEA Tiger, Inc., in the securities industry and as a director of other public companies qualifies him to serve as a director of the Company.
Kevin Claudio resigned from the Company’s Board of Directors effective as of March 11, 2011. His resignation was not due to any disagreements with the Company.
Item 8.01 Other Events
On March 2, 2011, the Company received notice that the Superior Court of the State of California, County of Orange (the “Court”) had granted Bluewater Partners, S.A. (“Bluewater”) request for a default judgment in the amount of $647,254.18 in the previously announced litigation involving the Bluewater promissory notes with the Company. The Company does not have the cash to pay the judgment and expects the default judgment to have a material adverse effect on the Company and its assets.
On March 8, 2011, the Superior Court of California, County of San Diego granted Gordon & Rees LLP’s request for a default judgment in the amount of $110,938.18 in the previously announced lawsuit against the Company. The Company does not have the cash to pay the judgment and expects the default judgment to have a material adverse effect on the Company and its assets.
NewCardio Study of my3KG Performance in Diagnosis of AMI Selected for Presentation at the Society for Academic Emergency Medicine Annual Meeting
Study Done in Collaboration with Emergency Medicine and Cardiology Experts from University of Minnesota and Kansas University Medical Center
SANTA CLARA, Calif., March 10, 2011 /PRNewswire/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiovascular diagnostic solutions developer, announced today that the results of a my3KG performance study will be made at the Society for Academic Emergency Medicine (SAEM) Annual Meeting, to be held in Boston, MA, June 1-5, 2011.
The study, entitled "A New Computer Algorithm Performs Better than Cardiologists in the Diagnosis of Acute Myocardial Infarction," will be presented at the SAEM meeting by Dr. Stephen W. Smith, Associate Professor of Emergency Medicine, University of Minnesota and Hennepin County Medical Center (HCMC), Minneapolis MN. Co-investigators in this study included Drs. Victor Romo and James Miner, Emergency Medicine, HCMC; and Drs. Dajuanna Lakireddy, Subba Vanga, and Sudha Bommana, Kansas University Cardiovascular Research Institute, Kansas City, KS.
The SAEM presentation will address a key diagnostic problem in Emergency Department (ED) patients – the low diagnostic sensitivity of the standard 12-lead ECG in early diagnosis of acute myocardial infarction (MI).
Dr. Smith commented, "The standard 12-lead ECG plays a critical role in MI diagnosis, but its low sensitivity – even with expert physician interpretation - leads to diagnostic delays and errors. To the extent that my3KG can improve diagnostic sensitivity for acute MI, it is an important result that may lead to faster and more accurate MI diagnosis in the ED."
Dr. Ihor Gussak, NewCardio's Chief Medical Officer, commented, "We were delighted that Dr. Smith collaborated with us in this study. He is an internationally known and well-respected emergency medicine specialist with particular expertise in clinical electrocardiology and diagnosis of acute coronary syndromes. He is highly influential among ED physicians, who represent a key potential constituency for my3KG. We look forward to the SAEM presentation, and to completing additional studies with Dr. Smith and his colleagues, as we further develop my3KG."
NewCardio's innovative 3-D ECG platform technology dramatically improves the accuracy and significantly increases the diagnostic value of the standard 12L ECG. NewCardio is developing the my3KG solution for urgent diagnosis of serious cardiac conditions, including AMI. In clinical studies to date, the my3KG has shown substantially improved diagnostic accuracy relative to the standard 12L ECG, particularly in the most diagnostically challenging patients (such as those with diabetes and electrical conduction abnormalities). Accordingly, the Company believes that its innovative my3KG solution will substantially improve diagnostic timing and accuracy in life-threatening cardiac conditions, and will thereby improve clinical outcomes for a broad range of cardiac patients. The Company plans to file a 510(k) application in late 2011 or early 2012 for FDA approval to market my3KG in the U.S.
About the Society for Academic Emergency Medicine (SAEM)
The SAEM is dedicated to the improvement of care of the acutely ill and injured patient by improving research and education. To achieve this mission, SAEM influences health policy through forums, publications, inter-organizational collaboration, policy development, and consultation services for physicians, teachers, researchers, and students. SAEM represents excellence and leadership in academic emergency medicine and its values include idealism and quality in all endeavors, nurturing and camaraderie and diversity among members, as well as creative and symbiotic interactions with other organizations.